Short- versus Long-Course Antibacterial Therapy for Community-Acquired Pneumonia

Alfa Institute of Biomedical Sciences (AIBS), Athens, GreeceDepartment of Critical Care, Attikon University Hospital, University of Athens, Athens, Greece.
Drugs (Impact Factor: 4.13). 09/2008; 68(13):1841-54. DOI: 10.2165/00003495-200868130-00004
Source: PubMed

ABSTRACT The evidence for traditionally recommended 7- to 14-day duration of antibacterial therapy for community-acquired pneumonia (CAP) is not well established.
We endeavoured to assess the effectiveness and safety of shorter than traditionally recommended antibacterial therapy for CAP.
We performed a meta-analysis of randomized controlled trials (RCTs) comparing short- (< or = 7 days) versus long- (> or = 2 days difference) course therapy for CAP with the same antibacterial regimens, in the same daily dosages.
Five RCTs involving adults (including outpatients and inpatients who did not require intensive care) and two RCTs involving children (aged 2-59 months, residing in developing countries) were included. All RCTs were double-blind and assessed patients with CAP of mild to moderate severity. No differences were found between short- (adults 3-7 days; children 3 days) and long- (adults 7-10 days; children 5 days) course regimens (adults - amoxicillin, cefuroxime, ceftriaxone, telithromycin and gemifloxacin; children - amoxicillin) regarding clinical success at end-of-therapy (six RCTs; 5107 patients [1095 adults, 4012 children]; fixed-effect model [FEM]; odds ratio [OR] = 0.89; 95% CI 0.74, 1.07), clinical success at late follow-up, microbiological success, relapses, mortality (seven RCTs; 5438 patients; FEM; OR = 0.57; 95% CI 0.23, 1.43), adverse events (five RCTs; 3214 patients; FEM; OR = 0. 90; 95% CI 0.72, 1.13) or withdrawals as a result of adverse events. No differences were found in subset analyses of adults or children, and of patients treated with no more than 5-day short-course regimens versus at least 7-day long-course regimens.
No difference was found in the effectiveness and safety of short- versus long-course antimicrobial treatment of adult and paediatric patients with CAP of mild to moderate severity.

Download full-text


Available from: Alexandros P Grammatikos, Feb 13, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Despite the constantly increasing need for new antimicrobial agents, antibiotic drug discovery and development seem to have greatly decelerated in recent years. Presented with the significant problem of advancing antimicrobial resistance, the global scientific community has attempted to find alternative solutions; one of the most promising ones is the evaluation and use of old antibiotic compounds. Due to the low-level use of many of the old antibiotic compounds, these have remained active against a large number of currently prevalent bacterial isolates. Thus, clinicians are beginning to re-evaluate their use in various patient populations and infections, despite the fact that they were previously thought to be less effective and/or more toxic than newer agents. A number of old antibiotic compounds, such as polymyxins, fosfomycin, fusidic acid, cotrimoxazole, aminoglycosides and chloramphenicol, are re-emerging as valuable alternatives for the treatment of difficult-to-treat infections. The availability of novel genetic and molecular modification methods provides hope that the toxicity and efficacy drawbacks presented by some of these agents can be surpassed in the future.
    Expert Review of Anticancer Therapy 11/2008; 6(5):593-600. DOI:10.1586/14787210.6.5.593 · 3.06 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim is to describe recent advances concerning pneumonia in older patients in relation to epidemiology, microbiology, and factors related to severity, treatment, and prevention. This article is a review of recent studies (2007 and 2008) on pneumonia in older people. The incidence of oropharyngeal dysphagia is increasing among older people. Biological markers of prognosis and severity do not normally offer additional relevant information to clinical data. Viral cause is increasingly relevant, and mixed infections are more severe and affect more old people. A new index has been developed (SMART-COP), which complements the existing Pneumonia Severity Index (PSI) and CURB-65 by improving identification of patients who require intensive care and vasopressor drugs. Reduction in antibiotic treatment duration is not associated with greater mortality or more readmissions. New developments regarding prevention of aspiration pneumonia and the utility of influenza and pneumococcal vaccines are discussed. Pneumonia is increasingly caused by viral pathogens, and the pneumococcal and influenza vaccines may not be as effective as was first published. Recent studies have shown that aspiration is an increasing risk factor for pneumonia among older people.
    Current opinion in pulmonary medicine 04/2009; 15(3):223-9. DOI:10.1097/MCP.0b013e328326f571 · 2.96 Impact Factor